Navigation Links
HUYA Bioscience Announces New Partnership with a High Profile Pharmaceutical Lab at Shanghai's Prestigious Fudan University
Date:3/20/2012

SAN DIEGO, March 20, 2012 /PRNewswire/ -- HUYA Bioscience International announced today a critical strategic partnership with one of China's preeminent pharmacological researchers, Prof. Deyong Ye of Fudan University's School of Pharmacy.  HUYA is an international leader in supporting the global development of China's pharmaceutical innovations.  Their new partnership with Fudan University will focus on specific innovations coming out of Prof. Deyong  Ye's lab that could meet critical global pharmaceutical needs.

Prof. Ye is currently vice director of the Department of Medicinal Chemistry at the School of Pharmacy.  His lab specializes in drug design and synthesis, including computer modeling of the three dimensional structures of enzymes such as sphingomyelin synthase (SMS).  Using those structures, the lab is designing drugs that will work as SMS inhibitors to target and combat diseases, including metabolic disease and cardiovascular disease.  The lab has been awarded multiple grants in this field and is at the forefront of China's efforts to promote innovative drug design.

The new partnership between HUYA and Prof. Ye's lab will enable both parties to collaborate to promote new drug development in China and worldwide.  The lab will be able to consult with HUYA's wide range of experts in drug development and globalization.  In turn, HUYA will have the first opportunity to evaluate certain research and development projects conducted at the lab, and will provide support and assistance as needed.

"Working with labs such as Prof. Deyong Ye's puts us at the cutting edge of drug innovation and development in China," said Clement Gingras, HUYA's Chief Technical Officer and COO, "We are honored by this opportunity and look forward to beneficial collaborations in the years to come." 

In Shanghai, Prof. Ye says he also welcomes this new partnership and is optimistic about its results:  "HUYA can provide the kind of expertise we need to accelerate the global reach of our innovative research and bring it to worldwide markets." 

ABOUT HUYA BIOSCIENCE INTERNATIONAL

HUYA is one of the first companies to have recognized China's potential to help meet the global demand for new preclinical and clinical stage compounds.  The company's strategy is to facilitate and promote the global development and commercialization of new drug compounds originating in China.  With eight offices strategically located across China, the most comprehensive Chinese compound portfolio in the world, and a growing number of exclusive agreements with premier Chinese research and development organizations, HUYA occupies a unique position with regards to the China bio-pharmaceutical industry.  Its strategy to identify and license novel Chinese compounds, and to offer Western pharmaceutical companies efficient and comprehensive access to therapeutic innovation in China, means the company can dramatically reduce the challenges of deal-making in China.  HUYA has become a champion in guiding China's biomedical innovations into the worldwide marketplace.  HUYA is jointly headquartered in Shanghai and in San Diego, California.  More information is available at www.huyabio.com.

ABOUT FUDAN UNIVERSITY'S SCHOOL OF PHARMACY

Fudan University's School of Pharmacy is one of the oldest and most prestigious pharmacology schools in China.  The school was founded in 1936, long before the founding of the People's Republic of China and right in the midst of the Japanese occupation. Originally part of the Shanghai Medical University, in 2000 the Medical University merged with Fudan University and the School of Pharmacy became officially part of Shanghai's most famous school of higher learning.  In the last decade, with the Chinese government's growing interest and focus on biotech and pharmacological research, the School of Pharmacy has attracted attention, funding and talent.  In early 2009 the School of Pharmacy relocated to Shanghai's Zhangjiang Hi-tech Park. 

CONTACT

USA:

Alisa Barba
Public Relations; HUYA Bioscience International
12531 High Bluff Drive, Suite 138
San Diego, CA 92130
Cell +1.619.417.7749
Email: abarba@huyabio.com

 


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences Reports Addition of New Scientific Articles to MANF Publications List
2. Regado Biosciences, Inc. to Present at the BIO-Europe Spring® 2012 Conference in Amsterdam, The Netherlands
3. Apricus Biosciences, Inc. (APRI) Transforms From Development Company to Income Generating!
4. Celling Biosciences Sponsors 7th Annual Stem Cell Summit
5. PuraMed BioScience®, Inc. Reports Increased Revenue From Sales of LipiGesic® M, Its Flagship Migraine Pain Relief Product
6. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
7. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
8. INVO Bioscience Announces Approval of INVOcell by Brazils ANVISA
9. Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
10. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
11. Roka Bioscience Awarded AOAC-RI Certification for Roka Listeria Detection Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has announced the ... MedCore" report to their offering. ... , Detachable coil embolization is ... malformations. The detachable coil embolization treatment of cerebral aneurysms is less invasive ... weakened area in the wall of an artery in the brain. This ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):